Valuation: Forte Biosciences, Inc.

Market Cap 1.94B 1.66B 1.55B 1.42B 2.67B 185B 2.7B 18.35B 7.15B 93.11B 7.27B 7.12B 308B P/E 2026 *
-19.4x
P/E 2027 * -18.9x
Enterprise Value 1.94B 1.66B 1.55B 1.42B 2.67B 185B 2.7B 18.35B 7.15B 93.11B 7.27B 7.12B 308B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.94%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Forte Biosciences, Inc.

1 day+0.04%
1 week+0.12%
Current month+0.42%
1 month+35.83%
3 months+256.28%
6 months+164.88%
Current year+182.07%
1 week 76.82
Extreme 76.82
76.95
1 month 54.64
Extreme 54.64
77.2
Current year 15.51
Extreme 15.51
77.2
1 year 10.11
Extreme 10.11
77.2
3 years 4.11
Extreme 4.11
77.2
5 years 4.11
Extreme 4.11
786.75
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 31/12/2017
Director of Finance/CFO 59 29/02/2020
Chief Operating Officer - 30/09/2020
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 31/05/2020
Director/Board Member 79 15/03/2022
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Fiscal year

Chief Financial Officer

884 0.0043%
01/07/26 Fiscal year

Chief Executive Officer

2,598 0.0127%
29/05/26 Free

Director

18,353 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%+0.12%+572.97%+270.79% 1.94B
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +1.13%+7.54%+110.48%+204.99% 29.14B
Weighted average by Cap. +0.74%+9.42%+61.45%+158.61%

Financials

2026 *2027 *
Net sales - -
Net income -91.11M -78.05M -73.03M -66.85M -125M -8.72B -127M -863M -336M -4.38B -342M -335M -14.48B -107M -92M -86.08M -78.8M -148M -10.28B -150M -1.02B -397M -5.16B -403M -395M -17.07B
Net Debt - -
Logo Forte Biosciences, Inc.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
23
Date Price Change Volume
21/08/26 US$76.92 +0.04% 2,012,128
20/08/26 US$76.89 -0.01% 3,196,160
19/08/26 US$76.90 +0.03% 6,480,148
18/08/26 US$76.88 -0.01% 771,129
17/08/26 US$76.89 +0.08% 558,158
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
76.92USD
Average target price
73.80USD
Spread / Average Target
-4.06%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock